Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial Reversal of chaperone activity loss of glycated αA-crystallin by a crosslink breaker Reversal Of Lens Protein Crosslinking And Aggregation By A Novel crosslink breaker The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes The Effect of the AGE crosslink breaker ALT-711 on Accommodation, Outflow Facility, IOP, and Anterior Segment Morphology Advanced Glycation Endproduct “AGE” Accumulation in Elderly Hypertensive Canines: Correlation with Effects of AGE crosslink breaker The thiamine analogue and advanced glycation endproducts crosslink breaker ALT-711 does not interfere with transketolase activity Effects of alagebrium, an advanced glycation end‐product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL … An agent cleaving glucose-derived protein crosslinks in vitro and in vivo Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure Therapeutic potential of breakers of advanced glycation end product–protein crosslinks Evaluation in vitro of AGE-crosslinks breaking ability of rosmarinic acid Advanced glycation end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis … and clinical improvements among patients with advanced heart failure treated with Alagebrium (a novel oral advanced glycation end-product crosslink breaker) Current therapeutic interventions in the glycation pathway: evidence from clinical studies The Effect of Advanced Glycation End Products (AGE) breaker, Alagebrium on the Cardiac Structural and Functional Change in Type I Diabetic Rat Model Evaluate the effect of Withania somnifera methanolic extracts as in-vitro antiglycating agents C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats1 The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes Effects of Advanced Glycation End-Product Inhibition and Protein Cross-Link Breaking in Diabetic Rats The putative antiglycation agent phenacylthiazolium bromide suppresses cellular triosephosphate accumulation in model hyperglycaemia in vitro by stimulating the … Alagebrium attenuates methylglyoxal induced oxidative stress and AGE formation in H9C2 cardiac myocytes Pharmacological therapy of age-related macular degeneration based on etiopathogenesis Effect of the AGE-breaker alagebrium on plasma and tissue advanced glycation end-products and sRAGE Extracellular glycation crosslinks: prospects for removal Factors influencing crosslink formation in muscle tissue Effect of advanced glycation end‐products (AGE) lowering drug ALT‐711 on biochemical, vascular, and bone parameters in a rat model of CKD‐MBD Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease Effects of alagebrium, an AGE breaker, on exercise tolerance and cardiac function in patients with chronic heart failure Effect of non-antihypertensive drugs on endothelial function in hypertensive subjects evaluated by flow-mediated vasodilation
Anti-steatotic and anti-inflammatory effects of Hovenia dulcis Thunb. extracts in chronic alcohol-fed rats Gynura procumbens reverses Acute and Chronic Ethanol-induced Liver steatosis through MAPK/SREBP-1c-Dependent and -Independent Pathways Understanding the effect of anthocyanin extracted from Lonicera caerulea L. on alcoholic hepatosteatosis alcohol abstinence rescues hepatic steatosis and liver injury via improving metabolic reprogramming in chronic alcohol-fed mice Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice alcohol-induced hepatic steatosis: A comparative study to identify possible indicator (s) of alcoholic fatty liver disease HIMH0021 attenuates ethanol-induced liver injury and steatosis in mice Oral intake of chicoric acid reduces acute alcohol-induced hepatic steatosis in mice Korean Red Ginseng attenuates ethanol-induced steatosis and oxidative stress via AMPK/Sirt1 activation Asperosaponin VI protects alcohol-induced hepatic steatosis and injury via regulating lipid metabolism and ER stress Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARα Methyl ferulic acid attenuates ethanol-induced hepatic steatosis by regulating AMPK and FoxO1 pathways in rats and L-02 cells Quercetin alleviates ethanol-induced liver steatosis associated with improvement of lipophagy Scopoletin prevents alcohol-induced hepatic lipid accumulation by modulating the AMPK–SREBP pathway in diet-induced obese mice Oroxylin A prevents alcohol-induced hepatic steatosis through inhibition of hypoxia inducible factor 1alpha Root bark of Ulmus davidiana var. japonica restrains acute alcohol-induced hepatic steatosis onset in mice by inhibiting ROS accumulation Humulus japonicus Extract Ameliorates hepatic steatosis Through the PPARα-Mediated Suppression of alcohol-induced Oxidative Stress Effect of soyasaponins-rich extract from soybean on acute alcohol-induced hepatotoxicity in mice Lactobacillus plantarum ZY08 relieves chronic alcohol-induced hepatic steatosis and liver injury in mice via restoring intestinal flora homeostasis Baicalin ameliorates alcohol-induced hepatic steatosis by suppressing SREBP1c elicited PNPLA3 competitive binding to ATGL hepatic peroxisome proliferator‐activated receptor gamma signaling contributes to alcohol‐induced hepatic steatosis and inflammation in mice Betaine in ameliorating alcohol-induced hepatic steatosis Reversal of ethanol-induced hepatic steatosis and lipid peroxidation by taurine: a study in rats Depdc5 deficiency exacerbates alcohol-induced hepatic steatosis via suppression of PPARα pathway Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress Mesencephalic astrocyte-derived neurotrophic factor alleviates alcohol induced hepatic steatosis via activating Stat3-mediated autophagy Monounsaturated fatty acid-enriched olive oil exacerbates chronic alcohol-induced hepatic steatosis and liver injury in C57BL/6J mice NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice Caffeic acid dimethyl ether alleviates alcohol-induced hepatic steatosis via microRNA-378b-mediated CaMKK2-AMPK pathway Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy Sympathetic overdrive and unrestrained adipose lipolysis drive alcohol-induced hepatic steatosis in rodents Inhibition of Ghrelin Activity by Receptor Antagonist [d-Lys-3] GHRP-6 Attenuates alcohol-induced hepatic steatosis by Regulating hepatic Lipid Metabolism miR-203 inhibits alcohol-induced hepatic steatosis by targeting lipin1 A plasma untargeted metabolomic study of Chinese medicine Zhi-Zi-Da-Huang decoction intervention to alcohol-induced hepatic steatosis Disturbances in the murine hepatic circadian clock in alcohol-induced hepatic steatosis Gomisin N alleviates ethanol-induced liver injury through ameliorating lipid metabolism and oxidative stress Ethanol-induced hepatic
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet–Induced fatty liver Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor–null mice with diet-induced insulin resistance Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet via activation of AMP-activated protein kinase Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid peroxidation in fructose-fed rats Polysaccharide from fuzi (FPS) prevents hypercholesterolemia in rats Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese Zucker rats ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically … Ascorbic acid supplementation prevents hyperlipidemia and improves myocardial performance in streptozotocin-diabetic rats Ingestion of guar gum hydrolysate, a soluble and fermentable nondigestible saccharide, improves glucose intolerance and prevents hypertriglyceridemia in rats fed … Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes Taurine prevents hypercholesterolemia in ovariectomized rats fed corn oil but not in those fed coconut oil BHUx: A patented polyherbal formulation to prevent hyperlipidemia and atherosclerosis JTT-501, a new oral hypoglycemic agent, reverses hypertriglyceridemia in Zucker fatty and ventromedial hypothalamus-lesioned obese rats Failure of Corn Oil and Triparanol to prevent hypercholesterolemia and Atherosclerosis. Ingestion of sugar-beet fiber prevents hypercholesterolemia induced by Ovariectomy in rats Leptin reverses hyperlipidemia and Vascular Dysfunction in Mice Exposed to Intermittent Hypoxia Deletion of JNK2 prevents hypercholesterolemia-Induced Oxidative Stress and Endothelial Dysfunction ω-3 IN CHANNA MICROPELTES (GIANT SNAKEHEAD FISH) prevent hypercholesterolemia AND INFLAMMATORY ACTIVITIES IN CHOLESTEROL-FED … Ingestion of sugar-beet fiber prevents hypercholesterolemia induced by ovariectomy in rats GREEN TEA CONSUMPTION prevents hypercholesterolemia AND OBESITY: A CROSS SECTION STUDY Ingestion of sugar-beet fiber prevents hypercholesterolemia induced by ovariectomy in rats Use of nutritional supplements for the prevention and treatment of hypercholesterolemia preventing dyslipidemia by Chlorella pyrenoidosa in rats and hamsters after chronic high fat diet treatment Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Alfalfa saponins and alfalfa seeds: Dietary effects in cholesterol-fed rabbits Effect of Lactobacillus reuteri on the prevention of hypercholesterolemia in mice Dietary flax seed in prevention of hypercholesterolemic atherosclerosis Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice Management of toxicity associated with nucleoside analogues or how to switch drugs without increasing the regimen's complexity SCD1 is essential for the prevention of hypercholesterolemia and hepatic dysfunction elicited by a very low‐fat, high carbohydrate diet Metabolic syndrome: effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity Adsorption of bile acid by chitosan-orotic acid salt and its application as an oral preparation Lipoprotein subfraction changes after continuous or intermittent exercise training. Renoprotective and lipid‐lowering effects of LR compounds, Novel advanced glycation end product inhibitors, in streptozotocin‐induced diabetic rats Effect of Aluminum Hydroxide Gels on
Metformin reverses fatty liver disease in obese, leptin-deficient mice Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice Spirulina maxima prevents fatty liver formation in CD-1 male and female mice with experimental diabetes ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats Enalapril prevents fatty liver in nephrotic rats. Nutritional and management strategies for the prevention of fatty liver in dairy cattle Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver A novel aminosterol reverses diabetes and fatty liver disease in obese mice … disease and nonalcoholic steatohepatitis suggest a new therapeutic approach: Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese … Arachidonic acid prevents fatty liver induced by conjugated linoleic acid in mice Retracted: Genistein improves liver function and attenuates non‐alcoholic fatty liver disease in a rat model of insulin resistance An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver Regular exercise prevents high-sucrose diet-induced fatty liver via improvement of hepatic lipid metabolism Studies on the preventive effect of Spirulina maxima on fatty liver development induced by carbon tetrachloride, in the rat Prevention of fatty liver in transition dairy cows by subcutaneous injections of glucagon Fish oil prevents sucrose‐induced fatty liver but exacerbates high‐safflower oil‐induced fatty liver in ddy mice … Non-Alcoholic Steatohepatitis (NASH) suggest a new therapeutic approach: Lin Hz, Yang SQ, Chuckaree C, et al., Metformin's reverses fatty liver Disease in Obese … Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met Nonalcoholic fatty liver disease: a challenge for pediatricians Dietary carbohydrate stimulates alcohol diet ingestion, promotes growth and prevents fatty liver in rats Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease Protective effect of Arthrospira maxima on fatty acid composition in fatty liver Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH) Arthrospira maxima prevents the acute fatty liver induced by the administration of simvastatin, ethanol and a hypercholesterolemic diet to mice Metabolic and nutritional considerations in nonalcoholic fatty liver Nonalcoholic fatty liver disease: an agenda for clinical research Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study Reply to'TNF-α is not the cause of fatty liver disease in obese diabetic mice' Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease Nonalcoholic fatty liver disease: a review of current understanding and future impact Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice fatty liver: You Can Reverse it Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet Invited review: pathology, etiology, prevention, and treatment of fatty liver in dairy cows fatty liver:
Sirtuin functions in health and disease Sirtuin chemical mechanisms Sirtuin activators From sirtuin biology to human diseases: an update Sirtuin activators and inhibitors Sirtuin catalysis and regulation Biological and potential therapeutic roles of sirtuin deacetylases Structural basis for sirtuin function: what we know and what we don't Sirtuin deacetylases in neurodegenerative diseases of aging The Sirtuin family: therapeutic targets to treat diseases of aging Sirtuin inhibitors Sirtuin 1 in lipid metabolism and obesity Sirtuin regulation in aging and injury A molecular mechanism for direct sirtuin activation by resveratrol Sirtuin 1 and sirtuin 3: physiological modulators of metabolism The sirtuin family's role in aging and age-associated pathologies Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation Emerging role of sirtuin 2 in the regulation of mammalian metabolism SIRTUIN 1: regulating the regulator Sirtuin activators mimic caloric restriction and delay ageing in metazoans Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling Sirtuin deacylases: a molecular link between metabolism and immunity Sirtuin-1 regulation of mammalian metabolism Sirtuin and metabolic kidney disease Structural basis for sirtuin activity and inhibition Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1 Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Redox Regulation of Sirtuin-1 by S-Glutathiolation Sirtuin inhibitors as anticancer agents Sirtuin 6: a review of biological effects and potential therapeutic properties The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening Altered sirtuin expression is associated with node-positive breast cancer The sirtuin SIRT6 regulates lifespan in male mice Sirtuin 1 in malignant transformation: friend or foe? Involvement of mammalian sirtuin 1 in the action of ethanol in the liver Regulation of sirtuin function by posttranslational modifications Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity Sirtuin-1 and HIV-1: an overview The human sirtuin family: evolutionary divergences and functions Targeting sirtuin 1 to improve metabolism: all you need is NAD+? The diversity of histone versus nonhistone sirtuin substrates A novel continuous assay for the deacylase sirtuin 5 and other deacetylases Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease The life span-prolonging effect of sirtuin-1 is mediated by autophagy Sirtuin 1 regulation of developmental genes during differentiation of stem cells Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease Sirtuin 3–dependent mitochondrial dynamic improvements protect against acute kidney injury Sirtuin 1: a target for kidney diseases Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α Proteolipid protein is required for transport of sirtuin 2 into CNS myelin Sirtuin 1 in immune regulation and autoimmunity Renal protective effect of sirtuin 1 Role of Sirtuin 1 in metabolic regulation Neuroprotective Sirtuin ratio reversed by ApoE4 Vitamin B3 and sirtuin function The Structural Basis of Sirtuin Substrate Affinity, Sirtuin-7 inhibits the activity of hypoxia-inducible factors Nonenzymatic protein acylation as a carbon stress regulated by sirtuin deacylases Sirtuin 1 (SIRT1) the misunderstood HDAC Oxidative stress, glutathione status, sirtuin and cellular stress response
Glucose transporters in the 21st Century Facilitative glucose transporters Molecular biology of mammalian glucose transporters Expression of glucose transporters in cancers Glucose transporters: expression, regulation and cancer Molecular physiology of glucose transporters Glucose transporters Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures Kinetoplastid glucose transporters Functional properties and genomics of glucose transporters Glucose transporters: structure, function and consequences of deficiency Glucose transport and glucose transporters in muscle and their metabolic regulation Biology of human sodium glucose transporters Two glucose transporters in Saccharomyces cerevisiae are glucose sensors that generate a signal for induction of gene expression Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes Glucose transporters serve as water channels. Facilitative glucose transporters: an expanding family Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus Glucose transporters in cancer metabolism Distribution of the glucose transporters in human brain tumors The mammalian glucose transporters. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins Molecular basis of ligand recognition and transport by glucose transporters Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters Current topic: glucose transporters in the human placenta Facilitated glucose transporters in epithelial cells Glucose transporters in preimplantation development Expression of glucose transporters in head‐and‐neck tumors Mammalian glucose transporters: structure and molecular regulation Brain glucose transporters: relationship to local energy demand Immunohistochemical localization and quantification of glucose transporters in the mouse brain Glucose transporters in cardiac metabolism and hypertrophy Facilitative glucose transporters: regulatory mechanisms and dysregulation in diabetes. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells Exercise-induced translocation of skeletal muscle glucose transporters Crystal structure of a bacterial homologue of glucose transporters GLUT1–4 The role of glucose transporters in brain disease: diabetes and Alzheimer's disease Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes Insulin‐induced translocation of glucose transporters in rat hindlimb muscles Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease Roles of multiple glucose transporters in Saccharomyces cerevisiae Exercise training, glucose transporters, and glucose transport in rat skeletal muscles Expression and regulation of glucose transporters in the bovine mammary gland Functional architecture of MFS D-glucose transporters Mammalian passive glucose transporters: members of an ubiquitous family of active and passive transport proteins Glucose transporters in the transepithelial transport of glucose Brain glucose transporters: implications for neurologic disease Regulation of glucose transporters by insulin and extracellular glucose in C2C12 myotubes Skeletal muscle plasma membrane glucose transport and glucose transporters after exercise Functional expression of sodium-glucose transporters in cancer Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. Changes in glucose transporters in muscle in response to exercise Insulin regulation of the two glucose transporters in 3T3-L1 adipocytes. Abundance, localization, and insulin-induced translocation of
STZ transport and cytotoxicity: specific enhancement in GLUT2-expressing cells Sugar absorption in the intestine: the role of GLUT2 Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. GLUT2, glucose sensing and glucose homeostasis The role of GLUT2 in dietary sugar handling Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. GLUT2 mutations, translocation, and receptor function in diet sugar managing Apical GLUT2: a major pathway of intestinal sugar absorption GLUT2 is a high affinity glucosamine transporter Inhibition of the intestinal glucose transporter GLUT2 by flavonoids GLUT2 in pancreatic and extra-pancreatic gluco-detection Simple‐sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2‐null mice Mechanisms of glucose uptake in intestinal cell lines: role of GLUT2 The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing Evidence from glut2-null mice that glucose is a critical physiological regulator of feeding Glucose uptake, utilization, and signaling in GLUT2-null islets. The regulation of K‐and L‐cell activity by GLUT2 and the calcium‐sensing receptor CasR in rat small intestine Insulin internalizes GLUT2 in the enterocytes of healthy but not insulin-resistant mice SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma Association of GLUT2 and TAS1R2 genotypes with risk for dental caries Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2 Transgenic reexpression of GLUT1 or GLUT2 in pancreatic β cells rescues GLUT2-null mice from early death and restores normal glucose-stimulated insulin secretion Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome The loss of GLUT2 expression by glucose-unresponsive beta cells of db/db mice is reversible and is induced by the diabetic environment. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2 Absorption of anthocyanins through intestinal epithelial cells–Putative involvement of GLUT2 Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model A mutation in the Glut2 glucose transporter gene of a diabetic patient abolishes transport activity. GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus Intestinal dehydroascorbic acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8 Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2 The diffusive component of intestinal glucose absorption is mediated by the glucose-induced recruitment of GLUT2 to the brush-border membrane Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system GLUT2 is the transporter for fructose across the rat intestinal basolateral membrane Is GLUT2 required for glucose sensing? Identification and functional characterization of the peroxisomal proliferator response element in rat
Pharmacological aspects of the safety of gliflozins CaMKII and GLUT1 in heart failure and the role of gliflozins Ultrasound-assisted dispersive liquid–liquid microextraction for determination of three gliflozins in human plasma by HPLC/DAD Postoperative euglycaemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the … Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes The good, the bad, and the ugly: sodium–glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes The synthesis of gliflozins … II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins Long-term efficacy of gliflozins versus gliptins for Type 2 Diabetes after metformin failure: a systematic review and network meta-analysis Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological … SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins Are gliflozins the new statins for diabetes? Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre … Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function Gliflozins–a new border stone euglycemic Diabetic Ketoacidosis In The Perioperative Period: Why Gliflozins May Not Be So Sweet After All! Selecting Patients at Risk of Developing DKA on Gliflozins PDB91-EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM A review on analytical methods for determination of oral anti-diabetic drugs like biguanides, gliptins and gliflozins in bulk and in pharmaceutical dosage forms Pharmacological characterization of the sodium-glicose co-transporter 2 inhibitors, gliflozins in isolated platelets from healthy volunteers Article Details summary of chromatographic analysis methods of anti diabetic gliflozins Empagliflozin, Canagliflozin and Dapagliflozin Gliflozins: initial review of literature Summary of chromatographic analysis methods of anti diabetic gliflozins Empagliflozin, Canagliflozin and Dapagliflozin How we indicate oral antidiabetics today (from metformin to gliptins and gliflozins) Antidiabetic drugs from group of gliflozins and their role in pharmacotherapy of diabetes Cardiorenal protection with SGLT2 inhibitors (gliflozins): from EMPA-REG OUTCOME to CANVAS
FNDC5/irisin is not only a myokine but also an adipokine Irisin/FNDC5-An updated review Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway Irisin and FNDC5 in retrospect: an exercise hormone or a transmembrane receptor? Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT FNDC5: a novel player in metabolism and metabolic syndrome Fndc5 knockdown significantly decreased neural differentiation rate of mouse embryonic stem cells Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies New insights into the cellular activities of Fndc5/Irisin and its signaling pathways Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to … A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases Increased FNDC5/Irisin expression in human hepatocellular carcinoma Does PGC1α/FNDC5/BDNF elicit the beneficial effects of exercise on neurodegenerative disorders? Myostatin knockout drives browning of white adipose tissue through activating the AMPK‐PGC1α‐Fndc5 pathway in muscle FNDC5/Irisin inhibits pathological cardiac hypertrophy Fndc5 overexpression facilitated neural differentiation of mouse embryonic stem cells FNDC5/Irisin–their role in the nervous system and as a mediator for beneficial effects of exercise on the brain FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs FNDC5 alleviates hepatosteatosis by restoring AMPK/mTOR-mediated autophagy, fatty acid oxidation, and lipogenesis in mice FNDC5 is produced in the stomach and associated to body composition Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′ UTR The diagnostic value of FNDC5/irisin in renal cell cancer Progress and challenges in the biology of FNDC5 and irisin Glucocorticoid receptor positively regulates transcription of FNDC5 in the liver Can resistance exercise alter irisin levels and expression profiles of FNDC5 and UCP1 in rats? FNDC5 expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle Common Genetic Variation in the Human FNDC5 Locus, Encoding the Novel Muscle-Derived 'Browning' Factor Irisin, Determines Insulin Sensitivity FNDC5 attenuates obesity-induced cardiac hypertrophy by inactivating JAK2/STAT3-associated inflammation and oxidative stress Association of metabolic parameters and rs726344 in FNDC5 with serum irisin concentrations Effects of swimming exercise on serum Irisin and bone FNDC5
Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process Cross-link breakers as a new therapeutic approach to cardiovascular disease Potential clinical utility of advanced glycation end product cross-link breakers in age-and diabetes-associated disorders Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein AI The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation Potential Usefulness of AGE Cross–Link Breakers for Modulating the Progression of AMD Advanced glycation end-product cross-link breakers: a novel therapeutic pathway for cardiovascular disease Cross-link Breakers and Inhibitors Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links In vitro antiglycation and cross-link breaking activities of Sri Lankan low-grown orthodox orange pekoe grade black tea (Camellia sinensis L) Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link Inhibitors and breakers of advanced glycation endproducts (AGEs): a review Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage Restraining cross-links responsible for the mechanical properties of collagen fibers: natural and artificial Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes Biochemical process of AGEs formation in complications of hyperglycemia-induced diabetes and its pathological damage effects: A possible target for new drugs Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin‐induced diabetic rats: Preventive versus curative … Crosslink breakers: a new approach to cardiovascular therapy AGE, RAGE, and ROS in diabetic nephropathy Laser Sub–Fractionation to Assess the Elasticity of Ageing Human Bruch's Membrane: Reversal Implications for AMD Diabetic heart disease Advanced glycation end‐products (AGEs) and heart failure: pathophysiology and clinical implications Novel cross-link breaker based on zwitterion structure: Synthesis, structure and druggability studies Advanced Glycation End Products in Diabetes‐Associated Atherosclerosis and Renal Disease: Interventional Studies Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling The diabetic myocardium Arterial stiffness and cardiovascular therapy A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1‐c][1,2,4]‐triazines and Pyrazolo[5,1‐c][1,2,4]triazines as Potential Antidiabetic Agents Consensus ensemble neural network modeling of Maillard reaction inhibitors Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus Advanced Glycation End Product Cross‐Linking: Pathophysiologic Role and Therapeutic Target in Cardiovascular Disease Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications The AGE/RAGE axis in diabetes‐accelerated atherosclerosis